Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology

Connor P. O'Meara, Charles W. Armitage, Dean W. Andrew, Avinash Kollipara, Nils Y. Lycke, Andrew A. Potter, Volker Gerdts, Nikolai Petrovsky, Kenneth W. Beagley

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Pathogens with a complex lifecycles can effectively evade host immunity in part due to each developmental stage expressing unique sets of antigens. Multisubunit vaccines incorporating signature antigens reflecting distinct developmental stages (multistage vaccines) have proven effective against viral, bacterial and parasitic infection at preventing pathogen evasion of host immunity. Chlamydia trachomatis is characterized by a biphasic extra/intracellular developmental cycle and an acute/persistent (latent) metabolic state; hence a multistage vaccine may prevent immune evasion and enhance clearance. Here we tested the efficacy of a multistage vaccine containing outer membrane (MOMP and PmpG), type three secretion system (T3SS) (CdsF and TC0873) and inclusion membrane proteins (IncA and TC0500) in mice against an intravaginal challenge with Chlamydia muridarum. Comparison of single (eg. MOMP) and double antigen vaccines (eg. MOMP and PmpG), largely targeting the extracellular stage, elicited significant yet comparable protection against vaginal shedding when compared to unimmunized control mice. Utilization of different adjuvants (ISCOMATRIX – IMX, PCEP/polyI:C/IDR1002 – VIDO, CTA1-DD and ADVAX) and numerous immunization routes (subcutaneous – SQ and intranasal – IN) further enhanced protection against infection. However, a multistage vaccine elicited significantly greater protection against vaginal shedding and upper genital tract pathology than vaccines targeting only extra- or intracellular stages. This indicates that protection elicited by a vaccine targeting extracellular chlamydial antigens could be improved by including chlamydial antigen expressed during intracellular phase.

    Original languageEnglish
    Pages (from-to)3883-3888
    Number of pages6
    JournalVaccine
    Volume35
    Issue number31
    DOIs
    Publication statusPublished - 5 Jul 2017

    Keywords

    • ADVAX
    • Chlamydia
    • CTA1-DD
    • ISCOMATRIX
    • PCEP
    • Vaccine

    Fingerprint Dive into the research topics of 'Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology'. Together they form a unique fingerprint.

  • Cite this